10times
22 Apr 2021Ended

Risk Assessment of Extractables and Leachables in Different Phases of Development

AboutSpeakersExhibitorsReviewsPhotos

Estimated Turnout

upto 100
Delegates
Based on previous editions

Editions

Apr 2021

Frequency

Not Available
Claim event to edit details

In order to ensure safety of patients, the toxicological risk assessment needs to thoroughly evaluate all potential risks which may be caused by any .. Read more component present in a pharmaceutical drug product. In consequence, the entry of E&L into the pharmaceutical product needs to be controlled and assessed. Adequate control of E&L requires an understanding of the materials used in production as well as the manufacturing process. As the knowledge on the manufacturing process evolves during the development of a drug product or medical device, it is advised to include learning cycles into the development program to avoid existence of critical E&Ls. These learning cycles offer the opportunity to increase the knowledge on E&L associated with the product over its development time. He started his professional career in 1990 at Schering AG, Berlin-Germany. From 2000-2006 he became Head of Animal Pharmacokinetics where he also successfully supervised the generation of two doctoral theses.

  • Share your Experience
  • Organizer
Logo Follow Company

BIOPHARMA ASIA MAGAZINE

South Korea72 Total Events / 12 Upcoming Events

More Events From The Organizer